The Serum Institute of India said in June they would be able to make and deliver nine to 10 doses of our Covishield vaccine in the country compared to our production capacity of 6.5 crore in May.
New Delhi: The Serum Institute of India (SII) has informed the government that it will be able to produce and supply 9 to 10 pounds of Covishield in June, official sources said on Sunday during international complaints about the shortage of anti-coronavirus jabs.
In a recent letter to Home Affairs Union Minister Amit Shah, SII said his workers had been working around the clock despite various challenges due to the epidemic.
“We are pleased to announce that in June we will be able to produce and supply nine to 10 volumes of our Covishield vaccine in the country compared to our production capacity of 6.5 crore in May,” said Prakash Kumar Singh, SII’s Director of Administration and Government, the letter said.
Mr Singh also thanked Mr Shah for his “valuable guidance and continued support” in various stages of their efforts to make India ” aatmanirbhar ” (self-sufficient) in the COVID-19 vaccine and make it available to the people of the country.
“The Serum Institute of India has been genuinely concerned about the protection of our national and international citizens in COVID-19. Under the leadership of our CEO, Adar C Poonawalla, our team has been working tirelessly with our government team to fight the COVID-19 epidemic. “he said in a letter.
“We assure you that with the help of the Government of India and under your kind guidance, we are trying our best to use all our resources to increase Covishield’s energy production next month as well.”
Earlier in May, SII had told the center that Covishield production would be upgraded to 6.5 crore in June, seven crore in July and 10 crore each in August and September.
India is currently using antiretroviral drugs developed in India – CII-based Covishield and Covaxin by Barat Biotech – in its COVID-19 vaccination program.
New Delhi: The Serum Institute of India (SII) has informed the government that it will be able to produce and supply 9 to 10 pounds of Covishield in June, official sources said on Sunday during international complaints about the shortage of anti-coronavirus jabs.
In a recent letter to Home Affairs Union Minister Amit Shah, SII said his workers had been working around the clock despite various challenges due to the epidemic.
“We are pleased to announce that in June we will be able to produce and supply nine to 10 volumes of our Covishield vaccine in the country compared to our production capacity of 6.5 crore in May,” said Prakash Kumar Singh, SII’s Director of Administration and Government, the letter said.
Mr Singh also thanked Mr Shah for his “valuable guidance and continued support” in various stages of their efforts to make India ” aatmanirbhar ” (self-sufficient) in the COVID-19 vaccine and make it available to the people of the country.
“The Serum Institute of India has been genuinely concerned about the protection of our national and international citizens in COVID-19. Under the leadership of our CEO, Adar C Poonawalla, our team has been working tirelessly with our government team to fight the COVID-19 epidemic. “he said in a letter.
“We assure you that with the help of the Government of India and under your kind guidance, we are trying our best to use all our resources to increase Covishield’s energy production next month as well.”
Earlier in May, SII had told the center that Covishield production would be upgraded to 6.5 crore in June, seven crore in July and 10 crore each in August and September.
India is currently using antiretroviral drugs developed in India – CII-based Covishield and Covaxin by Barat Biotech – in its COVID-19 vaccination program.